The neurology small molecule API market is experiencing significant growth driven by increasing neurological disorders, a rising geriatric population, and advancements in drug development. A major new study published in The Lancet Neurology reveals that, in 2021, over 3 billion people globally were living with a neurological condition. Neurological conditions have become the leading cause of ill health and disability worldwide, with the total burden of disability, illness, and premature death (disability-adjusted life years, DALYs) rising by 18% since 1990. This growing burden underscores the increasing demand for treatments and solutions in the market. Small molecule APIs, essential in treating conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis, are gaining traction due to their effectiveness and affordability compared to biologics. The demand for these APIs is further fueled by the ongoing research and development (R&D) efforts aimed at discovering novel treatments for complex neurological conditions with unmet medical needs.
